May 19 - AstraZeneca's Chairman explains why the UK drugmaker's board rejected a final ''sweetened'' offer from Pfizer. (Rough Cut - no reporter narration)
▲ Hide Transcript
▶ View Transcript
Britain's AstraZeneca rejected a sweetened and "final" offer from Pfize, puncturing the U.S. drugmaker's plan for a merger to create the world's biggest pharmaceuticals group.
The rebuff came nine hours after Pfizer said on Sunday night it had raised its takeover offer to 55 pounds a share, or around 70 billion pounds ($118 billion) in total, and would walk away if AstraZeneca did not accept it.
The rejection left some major shareholders fuming as shares in AstraZeneca slumped 11 percent to close at 42.88 pounds after falling as much as 15 percent - their biggest ever intra-day decline. Pfizer rose 1 percent in New York.
AstraZeneca Chairman Leif Johansson told Reuters he now saw no prospect of a deal with Pfizer before a deadline of May 26 set under British takeover rules, or any likelihood of that deadline being extended.
Experts also said Pfizer had left itself no room to return with a last-minute higher offer due to the strict takeover code.
Pfizer wants to create the world's largest drugs firm, with a headquarters in New York but a tax base in Britain, where corporate tax rates are lower than in the United States.
The plan has met entrenched opposition from AstraZeneca, as well as politicians and scientists who fear cuts to jobs and research.
Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code